Nasal Spray News and Research

RSS

Intranasal COVID-19 vaccine candidate preclinically tested at UAB expected to start clinical trial

The Altimmune Inc. vaccine candidate that was tested preclinically at the University of Alabama at Birmingham last year is expected to start patient enrollment for its Phase 1 clinical trial next week.

20 Feb 2021

Molecular modeling helps identify the binding site of antidepressantss

The effects of selective serotonin reuptake inhibitors (SSRIs) and other conventional antidepressants are believed to be based on their increasing the levels of serotonin and noradrenalin in synapses, while ketamine, a new rapid-acting antidepressant, is thought to function by inhibiting receptors for the neurotransmitter glutamate.

19 Feb 2021

Study provides new insight into the effects of antidepressant drugs

18 Feb 2021

Engineered peptide can reduce severe COVID-19 infection in humans

An engineered peptide given to ferrets two days before they were co-housed with SARS-CoV-2-infected animals prevented virus transmission to the treated ferrets, a new study shows.

18 Feb 2021

Nasal antiviral blocks SARS-CoV-2 transmission in ferrets

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the nasal spray also may prevent infection in people exposed to the new coronavirus, including recent variants.

17 Feb 2021

Nasodine antiseptic nasal spray shows potential antiviral activity against SARS-CoV-2

A team of international scientists has recently investigated the efficacy of PVP-1, a complex of polyvinylpyrrolidone and iodine, in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Using in vitro cell culture settings, the scientists observe that PVP-1 formulation used in a commercially available nasal spray (Nasodine) readily inactivates SARS-CoV-2 within a short period of time.

3 Feb 2021

New process separates beneficial glucocorticoids from unwanted side-effects

A collaboration led by Scripps Research has developed a way to separate the beneficial anti-inflammatory properties of a group of steroids called glucocorticoids from some of their unwanted side-effects, through an optimization process they named "ligand class analysis."

3 Feb 2021

Inhaling unfragmented hyaluronan improves lung function in COPD patients

Researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented hyaluronan improves lung function in patients suffering from severe exacerbation of chronic obstructive pulmonary disease (COPD).

1 Feb 2021

New nasal spray delivers antipsychotic medication directly to the brain

A team of neuroscientists and engineers at McMaster University has created a nasal spray to deliver antipsychotic medication directly to the brain instead of having it pass through the body.

16 Jan 2021

Researchers study the effectiveness of FEND product to improve airway hygiene

In a paper published in Molecular Frontiers Journal, researchers from Cambridge, Massachusetts and Bangalore, India study the effectiveness of FEND product to significantly improve airway hygiene by reducing and suppressing respiratory droplets potentially containing airborne pathogens and other contaminants.

12 Jan 2021

Eureka's InvisiMask human antibody nasal spray offers protection against SARS-CoV-2 in mice

Eureka Therapeutics, Inc. announced today successful preclinical results from its InvisiMask™ Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.

14 Dec 2020

UofL receives DoD funding to develop a nasal spray for preventing COVID-19

The University of Louisville has received funding from the U.S. Department of Defense (DoD) to develop a nasal spray to prevent serious viral respiratory infections such as COVID-19 using Q-Griffithsin, a drug compound developed and co-owned by UofL.

9 Dec 2020

Xylitol and grapefruit seed extract shows promise in preventing SARS-CoV-2 infection, study finds

A team of researchers at the Feinberg School of Medicine demonstrated that xylitol and grapefruit seed extract (GSE) could prevent SARS-CoV-2 infection. These can be used as a nasal spray to contain the spread of the coronavirus.

7 Dec 2020

Marinomed plans a clinical trial with Carragelose nasal spray as COVID-19 prophylaxis

Marinomed Biotech AG, a globally operating biopharmaceutical company, is pleased to announce today that the Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID).

30 Nov 2020

Marinomed to initiate clinical trial with Carragelose for preventing COVID19 in frontline healthcare staff

Marinomed Biotech AG, a globally operating biopharmaceutical company, announced today plans to initiate a Phase IV clinical trial with Carragelose (iota-carrageenan).

23 Nov 2020

Researchers develop nasal spray against COVID-19 virus

A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using materials already cleared for use in humans.

20 Nov 2020

Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection

A team of researchers at the University of Birmingham in the United Kingdom formulated a spray that contains polysaccharides known for their mucoadhesive antiviral properties for prophylaxis against SARS-CoV-2 infection.

19 Nov 2020

Xylitol and grapefruit seed extract nasal spray could help COVID-19 patients

United States based researchers have published a report exploring the potential role of Xylitol and Grapefruit seed extract (in the form of a nasal spray) in treating COVID-19.

16 Nov 2020

Nafamostat mesylate initially reduces SARS-CoV-2 viral loads in hamsters, study finds

Researchers have found that nafamostat mesylate, when injected in the nasal cavity of Syrian hamsters, can decrease initial SARS-CoV-2 viral loads in their nose. However, this effect was temporary and further testing is required to determine clinically significant effects. The research group's findings are available on the preprint server bioRxiv*.

11 Nov 2020

Nasal spray formulation of ivermectin for COVID-19 shows promise in pigs

Researchers in Argentina have conducted a pre-clinical study demonstrating the safety and pharmacokinetic performance of a new nasal spray formulation designed to suppress the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

26 Oct 2020